Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — H1 2021 Earnings Presentation
23 slides from Captor Therapeutics Sa's earnings presentation, Oct 6, 2021
Slide 1: Presentation of results for the first half of 2021
Presentation of results for the first half of 2021 6th October 2021 All images by Piotr Piatek
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Agenda
Agenda • COMPANY STRATEGY • R&D AND PIPELINE PROJECTS • BASIC ECONOMIC AND FINANCIAL DATA • OUTLOOK 2021+ 3
Slide 4: H1'2021 – key take-aways
H1’2021 – key take-aways BUSINESS FINANCES H1 2021 H1 2021 • 5 – projects in drug pipeline • ~150 M PLN – raised in successful IPO • 8 – pending PCT patent applications • ~92% - reduction of the retail tranche • 45% - percentage of scientific staff with a • ~8,7 M PLN – revenues refunded from NCBR P
Slide 5: Company Strategy
COMPANY STRATEGY 5
Slide 6: Captor Therapeutics: an ideal pharmaceutical synergy between Poland and Switzerland
Captor Therapeutics: an ideal pharmaceutical synergy between Poland and Switzerland Combine international expertise in A globally connected pharmaceutical Poland has highly qualified scientific Switzerland with local talent in Poland hub staff Access to experienced Polish cost base allows capital Le
Slide 7: Vision – become a world-leading drug discovery company based on targeted protein degradation
Vision – become a world-leading drug discovery company based on targeted protein degradation • Based in Wroclaw (Poland) and Basel (Switzerland) • Backed by private and non-dilutive public funds as well as funds raised in recent IPO Wroclaw, Poland Basel, Switzerland • Disruptive platform in drug di
Slide 8: An experienced leadership team
An experienced leadership team The Company is distinguished by an experienced leadership team with significant experience, with clear roles and responsibilities in innovation, commercialization of biopharmaceutical projects, operations and finance MANAGEMENT BOARD CO-FOUNDER Tom Shepherd, Ph.D. Mich
Slide 9: Three pillars of growth
Three pillars of growth The continued development of the platform will allow for the Platform continuous & sustainable creation development of new drug pipeline projects as pipeline drugs are commercialized Captor focuses on severe diseases Working to develop drug where there are a lack of candidate
Slide 10: Targeted protein degradation – a revolutionary approach
Targeted protein degradation – a revolutionary approach Targeted Protein Degradation (TPD) intervenes in diseases by removing pathological proteins Value of equity raised in Biotech • TPD drugs hold a promise of addressing unmet medical $140 needs through targeting pathological proteins inaccessible
Slide 11: R&D and Pipeline Projects
R&D AND PIPELINE PROJECTS 11
Slide 12: Stages of the research & development process
Stages of the research & development process Lead Candidate IND First in selection selection submission human Target selection Approval KEY MILESTONES ASSAYS LEAD PRECLINICAL CLINICAL PHASE II AND HIT-TO-LEAD IND REVIEW CLINICAL PHASE I AND SCREENING OPTIMIZATION DEVELOPMENT CLINICAL PHASE III TIMEL
Slide 13: Company pipeline projects
Company pipeline projects # Indications Modality Discovery Preclinical* INDFiling FIH** PROJEKT WSKAZANIE KLASA ZWIĄZKU ODKRYCIE I ROZWÓJ FAZA PRZEDKLINICZNA* FIH** Hepatocellular CT-01 carcinoma MG Rak wątrobowo - MG Autoimmunity komórkowy 2023 203 CT-02 Liquid tumors MG Liquid & solid MG 2023 CT-0
Slide 14: MCL-1 - a high potential oncology target
MCL-1 - a high potential oncology target MCL-1 has been a MCL-1 protects subject of intense research for many years, but no approved drug exists cancer cells from death CT-03 degraders can address Captor has multiple diseases, developed potent as MCL-1 is compounds that frequently altered CANCER deg
Slide 15: Basic Economic and Financial Data
BASIC ECONOMIC AND FINANCIAL DATA 15
Slide 16: Strong balance sheet as foundation for further development
Strong balance sheet as foundation for further development Data as of 30/06/2021 females males HIGHLY QUALIFIED PERSONNEL Number of employees 84 59 25 1. Number of research workers 76 51 25 Number of scientists with PhD 45% 28% 17% TANGIBLE FIXED ASSETS • Fixed assets as at 30/06/2021 amounted to PL
Slide 17: Selected financial data
Selected financial data REVENUES AND FINANCIAL RESULTS (PLN thousands) 1st half of 2021 1st half of 2020 Operating cost structure in H1 2021: 38% Research and development income 1 454 - • 46% - R&D expenditure 46% • 16% - Project overheads Other operating income 9 773 12 486 • 38% - General and admi
Slide 18: Outlook 2021+
OUTLOOK 2021+ 18
Slide 19: Outlook 2021+
Outlook 2021+ Further development of the pipeline, forecast to start the initial clinical phase for the most advanced projects in 2023 Expectation of entering into value creating contracts with further partners from the pharmaceutical and biotechnological sector, in addition to our cooperation with
Slide 20: Appendix
APPENDIX 20
Slide 21: Selected financial data
Selected financial data (data in thous. PLN) INTERIM CONDENSED CONSOLIDATED STATEMENT OF PERFORMANCE AND OTHER COMPREHENSIVE INCOME 01.01.2021- 01.01.2020- 30.06.2021 30.06.2020 Research and development income 1 454 - Cost of services sold - - Gross profit (loss) on sales 1 454 - Operating profit (l
Slide 22: Captor Therapeutics S.A contact details
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Polska Captor Therapeutics GmbH Gewerbestrasse 24 4123 Allschwil, Szwajcaria IR Contact: Marta Święcicka m.swiecicka@captortherapeutics.com Media and IR Contact: captortherapeutics@pov.pl All images by Piotr Piatek
Slide 23: Projects are co-financed by the European Regional Development Fund
Projects are co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19-00) Dis